Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Early detection of pancreatic ductal adenocarcinoma (PDAC) with a multiomic liquid biopsy.

View Full Paper
Ask AI
Bookmark
Share

Authors

HBHolly ButlerJCJames CameronDPDavid Palmer

Discussion

Loading...

Member takes

Overview

Randomized trial shows improved early detection of pancreatic ductal adenocarcinoma in high-risk populations, suggesting enhanced patient outcomes.

Key Points

  • The study aims to evaluate a novel multiomic liquid biopsy for early detection of pancreatic ductal adenocarcinoma in high-risk individuals.
  • Evaluated a spectroscopic blood test using infrared spectroscopy on blood samples.
  • Classified spectra from 166 PDAC patients against 459 symptomatic non-cancer patients.
  • Tested algorithms on an additional clinical dataset of 975 high-risk patients.
  • Initial ROC curve showed an AUC of 0.84 with 92% sensitivity and 52% specificity.
  • Stage-specific detection rates were 88% for stage I, 94% for stage II, 99% for stage III, and 95% for stage IV.
  • Validation testing confirmed diagnostic ability with AUC values of 0.81 for PDAC versus all controls and 0.83 for PDAC versus high-risk non-cancers.

Cite This Study

Butler et al. (2026) studied this question.

synapsesocial.com/papers/6a192f1bfab5b468c441875dhttps://doi.org/10.1200/jco.2026.44.16_suppl.4229
View Full Paper
Ask AI
Bookmark
Share